Ascentage Pharma prepares and tests GTPase KRAS (G12D mutant) inhibitors
March 29, 2023
Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have patented GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.